Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00897702 · ClinicalTrials.gov registry record
Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 269
- Enrollment target
NCT00897702: Completed study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00897702 is a clinical trial that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 269 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00897702 has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 269 participants
- Enrollment target
Study Summary
The purpose of this study is to learn why certain drugs stop working in patients.In lab studies, tumors become resistant in several ways. Specific molecules seem to change and this may be why therapy stops working. However, we do not know if the same molecules change in patients. This study is being done to see if they do change. If we learn more about how patients become resistant, we may be able to offer better treatment in the future.
Interventions
- OTHER Blood draw
- PROCEDURE biopsy
- OTHER immunoenzyme technique
- PROCEDURE histopathologic examination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 269 participants |
| Start Date | 2007-01-09 |
| Est. Completion | 2026-01-23 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00897702
The ClinicalTrials.gov registry entry for NCT00897702 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 269 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Blood draw is the first listed.
NCT00897702 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00897702 about?
NCT00897702 is a clinical study titled "Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer". The purpose of this study is to learn why certain drugs stop working in patients.In lab studies, tumors become resistant in several ways. Specific molecules seem to change and this may be why therapy stops working. However, we do not know if the same molecules change in patients. This study is being...
What is the current status of trial NCT00897702?
This trial is currently completed. The enrollment target is 269 participants. The study started on 2007-01-09. Estimated completion is 2026-01-23.
What interventions are being tested in trial NCT00897702?
The interventions under investigation include: Blood draw (OTHER), biopsy (PROCEDURE), immunoenzyme technique (OTHER), histopathologic examination (PROCEDURE).
Who is sponsoring clinical trial NCT00897702?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.